Artur Jurczyszyn

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Michel Attal, Paul G. Richardson, S. Vincent Rajkumar et al. · The Lancet · 2019 · 620 citations

Hematological Malignancy, Medicine, Immunology +6

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Pieter Sonneveld, Meletios Α. Dimopoulos, Mario Boccadoro et al. · New England Journal of Medicine · 2023 · 435 citations · Full text

Role of Magnetic Resonance Imaging in the Management of Patients With Multiple Myeloma: A Consensus Statement

Meletios Α. Dimopoulos, Jens Hillengaß, Saad Z. Usmani et al. · Journal of Clinical Oncology · 2015 · 387 citations · Full text

International Myeloma Working Group Recommendations for the Treatment of Multiple Myeloma–Related Bone Disease

Evangelos Terpos, Gareth J. Morgan, Meletios Α. Dimopoulos et al. · Journal of Clinical Oncology · 2013 · 352 citations · Full text

Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial

Sebastian Grosicki, Maryana Simonova, Ivan Špıčka et al. · The Lancet · 2020 · 310 citations · Full text

Hematological Malignancy, Once-per-week Selinexor, Medicine +7